Source Omega Home

Medical Omega-3 DHA Discussion

Good questions.  These are good results in the abstract.  Genomics studies with fish oil support these findings.  I would say DHA is the main omega-3 incorporated into cells and organ tissues in the cellular accretion process over those 12 weeks.  I personally believe the fish oil FDA hang-up over diabetes was based on badly done studies.  Glycemic control measurements have greatly improved, but we don't see ongoing reports of consumer side effects using fish oil. I'd currently say the two sources are equivalent for diabetics as far as we know, but the past perception might be there.  Algae oil is also a highly concentrated natural formulation of omega-3s that I simply point out matches human metabolism and tissue composition requirements.

I have already developed the fasting triglycerides protocol, that's easy to do. I also have adopted the DHA Alzheimer's clinical trial protocol for dementia concerns.  These are services your clinic could provide.  My art is the conclusion/hypothesis that Postprandial Triglycerides are/may be better treated by DHA algae oil.  Results expected with algae oil are that DHA effectively decreases postprandial triglycerides, and potentially decreases peak time after a meal and the duration of prolonged elevated triglycerides. My stamp after my postdoc was to create the first U.S. algae oil product to access the FDA's heart health claims.  By default we have access to brain benefit claims for DHA as the news keeps coming out.

That is why I say Pure One is the first Optimized Omega-3 for the Heart and the Brain. Source-Omega's Mission is to Deliver Measurable Omega-3 DHA Results.

Dr. Doughman, PhD  (a.k.a. DR DHA)

______________________

Ref:

Eur Rev Med Pharmacol Sci. 2009 Jan-Feb;13(1):51-5.  Effect of omega-3 fatty acids on cardiovascular risk factors in patients with type 2 diabetes mellitus and hypertriglyceridemia: an open study.

De Luis DA, Conde R, Aller R, Izaola O, González Sagrado M, Perez Castrillón JL, Dueñas A, Romero E.

Institute of Endocrinology and Nutrition, Medicine School and Hospital Rio Hortega, University of Valladolid, Valladolid, Spain. dadluis@yahoo.es

BACKGROUND AND OBJECTIVES: Epidemiological and interventional studies suggest that a high dietary intake of n-3 polyunsaturated fatty acids may confer a protective effect against atherosclerotic disease and reduce serum triglycerides levels. The aim of our study was to investigate the effectivity on triglyceride levels and inflammatory markers of a concentrated of n-3 fatty acids in patients with type 2 diabetes mellitus and hypertriglyceridaemia. SUBJECTS: A total of 30 patients (16 males and 14 females) with diabetes mellitus type 2 and hypertriglyceridemia (> 200 mg/dl) were included in the study.  Patients received two capsules of eicosapentaenoic 465 mg and docosahexanoic 375 mg daily for 12 weeks. RESULTS: Triglycerides levels and non HDL-cholesterol decreased (326 +/- 113.5 vs. 216.4 +/- 57 mg/dl; p < 0.05) and (103.87 +/- 44 vs. 89.6 +/- 14 mg/dl; p < 0.05), respectively. HDL-cholesterol levels increased (39.6 +/- 10.7 vs. 46.4 +/- 8.7 mg/dl; p < 0.05). C reactive protein decreased (5.98+/- 3.9 vs. 3.9 +/- 1.6 mg/dl; p < 0.05) and TNF-alpha levels

decreased (16.24 +/- 5.5 vs. 13.3 +/- 5.8 pg/dl; p < 0.05), without significant changes in IL-6 levels. In conclusion, an n-3 polyunsaturated intervention improved lipid profile and inflammatory markers in patients with diabetes mellitus type 2 and hypertriglyceridaemia.

PMID: 19364085